Myriad Genetics and BioMarin Advance PARP Collaboration Into Phase 3

Myriad Genetics and BioMarin Advance PARP Collaboration Into Phase 3

SALT LAKE CITY, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.
(Nasdaq:MYGN) today announced that BioMarin Pharmaceutical Inc. will use
Myriad's BRACAnalysis^® test in connection with its pivotal Phase 3 clinical
studies for BMN 673. BMN 673 is a novel, orally-active PARP inhibitor designed
to induce synthetic lethality in BRCA-deficient cells.

Myriad will collaborate with BioMarin to deliver BRAC testing for its pivotal
clinical studies. As required by the U.S. Food and Drug Administration, Myriad
also submitted an Investigational Device Exemption (IDE) to the FDA that will
allow for BRACAnalysis testing to be used as a companion diagnostic to
stratify patients in the BMN 673 clinical program. Additional terms of the
deal were not disclosed.

"Companion diagnostics are a major focus of our business and are increasingly
being integrated into drug development programs," said Mark C. Capone,
president of Myriad Genetics Laboratories. "BRACAnalysis has shown promise as
a companion diagnostic, and we are actively collaborating with BioMarin to
identify responders and non-responders to therapy with BioMarin's novel PARP
inhibitor."

"Through our experience working with the Myriad BRACAnalysis test in our Phase
1 trial for BMN 673 in solid tumors, we appreciate the investment that Myriad
has made in developing this assay and understanding its use," said Len Post,
vice president, Chief Scientific Officer Drug Discovery at BioMarin.
"Identifying the right patients to enroll in our Phase 3 study for BMN 673 in
BRCA breast cancer will be critical in answering important scientific
questions about the safety and efficacy of the compound in this select
population."

About BRACAnalysis^® Companion Diagnostics

BRACAnalysis is the gold standard molecular diagnostic test to confirm the
presence of a BRCA1 or BRCA 2 gene mutation. Previously published scientific
data have shown that patients with BRCA-mutated cancers may receive clinical
benefit from treatment with investigational PARP inhibitors. Myriad Genetics
has been developing BRACAnalysis as a companion diagnostic for several
years.The Company currently has six active collaborations with pharmaceutical
companies to develop a BRACAnalysis as a companion diagnostic for
investigational PARP inhibitors.In August, the FDA accepted the first
Investigational Device Exemption (IDE) for BRACAnalysis, enabling clinical
studies to include BRACAnalysis testing as a companion diagnostic. For more
information, visit www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making
a difference in patients' lives through the discovery and commercialization of
transformative tests to assess a person's risk of developing disease, guide
treatment decisions and assess risk of disease progression and recurrence.
Myriad's portfolio of molecular diagnostic tests are based on an understanding
of the role genes play in human disease and were developed with a commitment
to improving an individual's decision making process for monitoring and
treating disease. Myriad is focused on strategic directives to introduce new
products, including companion diagnostics, as well as expanding
internationally. For more information on how Myriad is making a difference,
please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, myRisk are trademarks or registered
trademarks of Myriad Genetics, Inc. in the United States and foreign
countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the use of Myriad's BRACAnalysis test as a companion diagnostic
to stratify patients in BioMarin's pivotal Phase 3 clinical studies for BMN
673;the submission and approval of BRACAnalysis testing for an
Investigational Device Exemption (IDE) with the U.S. Food and Drug
Administration (FDA) for BRACAnalysis testing to be used as a companion
diagnostic to identify potential responders to BMN 673 therapy in the United
States;and the offering of BRACAnalysis testing as a companion diagnostic --
following review by FDA -- to help select patients who are likely to respond
to poly ADP ribose polymerase (PARP) inhibitors; and the Company's strategic
directives under the caption "About Myriad Genetics".These "forward-looking
statements" are management's present expectations of future events and are
subject to a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those described in the forward-looking
statements. These risks include, but are not limited to: the risk that sales
and profit margins of our existing molecular diagnostic tests and companion
diagnostic services may decline or will not continue to increase at historical
rates; risks related to changes in the governmental or private insurers
reimbursement levels for our tests; the risk that we may be unable to develop
or achieve commercial success for additional molecular diagnostic tests and
companion diagnostic services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular diagnostic tests
and companion diagnostic services, including our ability to successfully
generate revenue outside the United States; the risk that licenses to the
technology underlying our molecular diagnostic tests and companion diagnostic
services tests and any future tests are terminated or cannot be maintained on
satisfactory terms; risks related to delays or other problems with operating
our laboratory testing facilities; risks related to public concern over our
genetic testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or healthcare
payment systems; risks related to our ability to obtain new corporate
collaborations or licenses and acquire new technologies or businesses on
satisfactory terms, if at all; risks related to our ability to successfully
integrate and derive benefits from any technologies or businesses that we
license or acquire; the development of competing tests and services; the risk
that we or our licensors may be unable to protect the proprietary technologies
underlying our tests; the risk of patent-infringement claims or challenges to
the validity of our patents; risks of new, changing and competitive
technologies and regulations in the United States and internationally; and
other factors discussed under the heading "Risk Factors" contained in Item 1A
in our most recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, as well as any updates to those risk factors filed from
time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. All information in this press release is as of the date of the release,
and Myriad undertakes no duty to update this information unless required by
law.

CONTACT: Media Contact: Ron Rogers
         (801) 584-3065
         rrogers@myriad.com
        
         Investor Contact: Scott Gleason
         (801) 584-1143
         sgleason@myriad.com